Abstract
Azole resistance in Aspergillus fumigatus is a One Health resistance threat, where azole fungicide exposure compromises the efficacy of medical azoles. The use of the recently authorized fungicide ipflufenoquin, which shares its mode-of-action with a new antifungal olorofim, underscores the need for risk assessment for dual use of antifungals.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 100885 |
Tidsskrift | Drug Resistance Updates |
Vol/bind | 65 |
ISSN | 1368-7646 |
DOI | |
Status | Udgivet - 2022 |
Bibliografisk note
Publisher Copyright:© 2022 The Authors